Dr. Roger G. Mazlen is a pharmacologist and internist in Roslyn, New York, who brings with him more than five decades of professional experience. Today, he excels in various roles with The SASS Foundation for Medical Research, Inc. Additionally, he diagnoses and treats patients via his practice, Mazlen Medical Arts, PC. With a demonstrated expertise in the science and research of the effect of drugs on the human body, he draws from his previous experiences in the medical field to elevate the projects that he works on.
Previously, Dr. Mazlen served as a senior attendant for the division of endocrinology and metabolism for Mount Sinai Medical Center, a role that held from 1972 to 2008. Further, he is recommended by the Mount Sinai Physician Referral Service. Other prominent roles held in his career include and assistant director of clinical research at Ayerst Laboratories; associate medical director of Pfizer Inc.; postdoctoral fellow with the Harvard Medical School at the Peter Bent Brigham Hospital; research associate with the National Institutes of Health; senior clinical assistant professor at Mount Sinai School of Medicine; and adjunct assistant professor of medicine at New York Medical College. He served as a director and secretary-treasurer of the American College of Nutrition.
Dr. Mazlen has made a name for himself in his industry due to his work on career-related projects. He was chief science officer of Biomolecular Sciences for seven years, nutritional director of Cernitin American Nutrition for five years, and director of clinical research for North America Immunotec, LTD. Additionally, he served as a consultant and expert medical lecturer for the SASS Foundation for Medical Research, as well as a consultant in clinical nutrition and metabolism at South Oaks Hospital where he was also an attending physician and internist.
Dr. Mazlen is the author of “A New Manifesto for Middle America” and co-author of “Nutrition and Health Care.” He also contributed a chapter to the medical text “Quick Reference to Clinical Nutrition.” During his time at Ayerst Laboratories, Dr. Mazlen developed and conducted clinical research studies leading to the approval of Inderal, the first beta-blocker to be used in medicine in the United States. This achievement, in addition to his 50 years of work, led Dr. Mazlen in obtaining a Top Doctor Award as a specialist in internal medicine from New York Magazine. He was also the recipient of a Good Doctors List Award.
Contact Roger G. Mazlen:
